- Home
- ASND vs REG Comparison
ASND vs REG Comparison
Compare ASND & REG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASND | REG |
|---|---|---|
| Founded | 2006 | 1963 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 12.8B |
| IPO Year | 2015 | 1993 |
Fundamental Metrics
Financial Performance| Metric | ASND | REG |
|---|---|---|
| Price | $215.37 | $67.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $256.40 | $78.90 |
| AVG Volume (30 Days) | 726.7K | ★ 1.1M |
| Earning Date | 11-12-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 4.46% |
| EPS Growth | N/A | ★ 2.61 |
| EPS | N/A | ★ 2.18 |
| Revenue | $758,592,045.00 | ★ $1,576,868,000.00 |
| Revenue This Year | $99.74 | $3.11 |
| Revenue Next Year | $79.40 | $4.13 |
| P/E Ratio | ★ N/A | $31.09 |
| Revenue Growth | ★ 97.46 | 5.84 |
| 52 Week Low | $118.03 | $63.44 |
| 52 Week High | $229.94 | $78.18 |
Technical Indicators
Market Signals| Indicator | ASND | REG |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 36.86 |
| Support Level | $192.28 | $67.10 |
| Resistance Level | $229.94 | $68.95 |
| Average True Range (ATR) | 10.28 | 0.95 |
| MACD | 0.84 | -0.21 |
| Stochastic Oscillator | 61.25 | 18.20 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.